Outcomes of Transcatheter Tricuspid Valve-in-Valve Implantation in Patients With Ebstein Anomaly

for the, VIVID Registry

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We sought to describe the acute results and short- to medium-term durability of transcatheter tricuspid valve-in-valve (TVIV) implantation within surgical bioprostheses among patients with Ebstein anomaly (EA). Cases were identified from a voluntary, multicenter, international registry of 29 institutions that perform TVIV. Demographic, clinical, procedural, and follow-up data were analyzed. Eighty-one patients with EA underwent TVIV from 2008 to 2016. Thirty-four patients (42%) were New York Heart Association (NYHA) class 3/4 at time of TVIV. The most common indication for TVIV was the presence of moderate or severe tricuspid regurgitation (40%). Most patients received a Melody valve (64%). TVIV was ultimately successful in all patients, and there was no procedural mortality. Four patients (5%) developed acute valve thrombosis, 4 patients (5%) developed endocarditis, and 9 patients (11%) developed valve dysfunction not related to thrombosis or endocarditis. Eight patients (10%) underwent reintervention (2 transcatheter, 6 surgical) due to thrombosis (3), endocarditis (2), other valve dysfunction (2), and patient-prosthesis mismatch without valve dysfunction (1). Among 69 patients who were alive without reintervention at latest follow-up, 96% of those with NYHA status reported were class 1/2, a significant improvement from baseline (62% NYHA class 1/2, p <0.001). In conclusion, transcatheter TVIV offers a low-risk, minimally invasive alternative to surgical tricuspid valve re-replacement in patients with EA and a failing tricuspid valve bioprosthesis.

Original languageEnglish (US)
Pages (from-to)262-268
Number of pages7
JournalAmerican Journal of Cardiology
Volume121
Issue number2
DOIs
StatePublished - Jan 15 2018
Externally publishedYes

Fingerprint

Ebstein Anomaly
Tricuspid Valve
Endocarditis
Bioprosthesis
Thrombosis
Tricuspid Valve Insufficiency
Surgical Instruments
Prostheses and Implants
Registries

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Outcomes of Transcatheter Tricuspid Valve-in-Valve Implantation in Patients With Ebstein Anomaly. / for the; VIVID Registry.

In: American Journal of Cardiology, Vol. 121, No. 2, 15.01.2018, p. 262-268.

Research output: Contribution to journalArticle

@article{84329dac719e4e64985498e50d1f793c,
title = "Outcomes of Transcatheter Tricuspid Valve-in-Valve Implantation in Patients With Ebstein Anomaly",
abstract = "We sought to describe the acute results and short- to medium-term durability of transcatheter tricuspid valve-in-valve (TVIV) implantation within surgical bioprostheses among patients with Ebstein anomaly (EA). Cases were identified from a voluntary, multicenter, international registry of 29 institutions that perform TVIV. Demographic, clinical, procedural, and follow-up data were analyzed. Eighty-one patients with EA underwent TVIV from 2008 to 2016. Thirty-four patients (42{\%}) were New York Heart Association (NYHA) class 3/4 at time of TVIV. The most common indication for TVIV was the presence of moderate or severe tricuspid regurgitation (40{\%}). Most patients received a Melody valve (64{\%}). TVIV was ultimately successful in all patients, and there was no procedural mortality. Four patients (5{\%}) developed acute valve thrombosis, 4 patients (5{\%}) developed endocarditis, and 9 patients (11{\%}) developed valve dysfunction not related to thrombosis or endocarditis. Eight patients (10{\%}) underwent reintervention (2 transcatheter, 6 surgical) due to thrombosis (3), endocarditis (2), other valve dysfunction (2), and patient-prosthesis mismatch without valve dysfunction (1). Among 69 patients who were alive without reintervention at latest follow-up, 96{\%} of those with NYHA status reported were class 1/2, a significant improvement from baseline (62{\%} NYHA class 1/2, p <0.001). In conclusion, transcatheter TVIV offers a low-risk, minimally invasive alternative to surgical tricuspid valve re-replacement in patients with EA and a failing tricuspid valve bioprosthesis.",
author = "{for the} and {VIVID Registry} and Taggart, {Nathaniel W.} and Cabalka, {Allison K.} and Andreas Eicken and Aboulhosn, {Jamil A.} and Thomson, {John D.R.} and Brian Whisenant and Bocks, {Martin L.} and Stephan Schubert and Jones, {Thomas K.} and Asnes, {Jeremy D.} and Fagan, {Thomas E.} and Jeffery Meadows and Mark Hoyer and Martin, {Mary H.} and Frank Ing and Turner, {Daniel R.} and Azeem Latib and Aphrodite Tzifa and Stephan Windecker and Goldstein, {Bryan H.} and Delaney, {Jeffrey W.} and Kuo, {James A.} and Susan Foerster and Matthew Gillespie and Gianfranco Butera and Shabana Shahanavaz and Eric Horlick and Younes Boudjemline and Daniel Dvir and McElhinney, {Doff B.}",
year = "2018",
month = "1",
day = "15",
doi = "10.1016/j.amjcard.2017.10.017",
language = "English (US)",
volume = "121",
pages = "262--268",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Outcomes of Transcatheter Tricuspid Valve-in-Valve Implantation in Patients With Ebstein Anomaly

AU - for the

AU - VIVID Registry

AU - Taggart, Nathaniel W.

AU - Cabalka, Allison K.

AU - Eicken, Andreas

AU - Aboulhosn, Jamil A.

AU - Thomson, John D.R.

AU - Whisenant, Brian

AU - Bocks, Martin L.

AU - Schubert, Stephan

AU - Jones, Thomas K.

AU - Asnes, Jeremy D.

AU - Fagan, Thomas E.

AU - Meadows, Jeffery

AU - Hoyer, Mark

AU - Martin, Mary H.

AU - Ing, Frank

AU - Turner, Daniel R.

AU - Latib, Azeem

AU - Tzifa, Aphrodite

AU - Windecker, Stephan

AU - Goldstein, Bryan H.

AU - Delaney, Jeffrey W.

AU - Kuo, James A.

AU - Foerster, Susan

AU - Gillespie, Matthew

AU - Butera, Gianfranco

AU - Shahanavaz, Shabana

AU - Horlick, Eric

AU - Boudjemline, Younes

AU - Dvir, Daniel

AU - McElhinney, Doff B.

PY - 2018/1/15

Y1 - 2018/1/15

N2 - We sought to describe the acute results and short- to medium-term durability of transcatheter tricuspid valve-in-valve (TVIV) implantation within surgical bioprostheses among patients with Ebstein anomaly (EA). Cases were identified from a voluntary, multicenter, international registry of 29 institutions that perform TVIV. Demographic, clinical, procedural, and follow-up data were analyzed. Eighty-one patients with EA underwent TVIV from 2008 to 2016. Thirty-four patients (42%) were New York Heart Association (NYHA) class 3/4 at time of TVIV. The most common indication for TVIV was the presence of moderate or severe tricuspid regurgitation (40%). Most patients received a Melody valve (64%). TVIV was ultimately successful in all patients, and there was no procedural mortality. Four patients (5%) developed acute valve thrombosis, 4 patients (5%) developed endocarditis, and 9 patients (11%) developed valve dysfunction not related to thrombosis or endocarditis. Eight patients (10%) underwent reintervention (2 transcatheter, 6 surgical) due to thrombosis (3), endocarditis (2), other valve dysfunction (2), and patient-prosthesis mismatch without valve dysfunction (1). Among 69 patients who were alive without reintervention at latest follow-up, 96% of those with NYHA status reported were class 1/2, a significant improvement from baseline (62% NYHA class 1/2, p <0.001). In conclusion, transcatheter TVIV offers a low-risk, minimally invasive alternative to surgical tricuspid valve re-replacement in patients with EA and a failing tricuspid valve bioprosthesis.

AB - We sought to describe the acute results and short- to medium-term durability of transcatheter tricuspid valve-in-valve (TVIV) implantation within surgical bioprostheses among patients with Ebstein anomaly (EA). Cases were identified from a voluntary, multicenter, international registry of 29 institutions that perform TVIV. Demographic, clinical, procedural, and follow-up data were analyzed. Eighty-one patients with EA underwent TVIV from 2008 to 2016. Thirty-four patients (42%) were New York Heart Association (NYHA) class 3/4 at time of TVIV. The most common indication for TVIV was the presence of moderate or severe tricuspid regurgitation (40%). Most patients received a Melody valve (64%). TVIV was ultimately successful in all patients, and there was no procedural mortality. Four patients (5%) developed acute valve thrombosis, 4 patients (5%) developed endocarditis, and 9 patients (11%) developed valve dysfunction not related to thrombosis or endocarditis. Eight patients (10%) underwent reintervention (2 transcatheter, 6 surgical) due to thrombosis (3), endocarditis (2), other valve dysfunction (2), and patient-prosthesis mismatch without valve dysfunction (1). Among 69 patients who were alive without reintervention at latest follow-up, 96% of those with NYHA status reported were class 1/2, a significant improvement from baseline (62% NYHA class 1/2, p <0.001). In conclusion, transcatheter TVIV offers a low-risk, minimally invasive alternative to surgical tricuspid valve re-replacement in patients with EA and a failing tricuspid valve bioprosthesis.

UR - http://www.scopus.com/inward/record.url?scp=85033779789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033779789&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2017.10.017

DO - 10.1016/j.amjcard.2017.10.017

M3 - Article

C2 - 29153244

AN - SCOPUS:85033779789

VL - 121

SP - 262

EP - 268

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 2

ER -